nodes	percent_of_prediction	percent_of_DWPC	metapath
Cevimeline—CYP2D6—Sorafenib—liver cancer	0.0228	0.38	CbGbCtD
Cevimeline—CYP3A4—Sorafenib—liver cancer	0.0145	0.242	CbGbCtD
Cevimeline—CYP2D6—Doxorubicin—liver cancer	0.0138	0.231	CbGbCtD
Cevimeline—CYP3A4—Doxorubicin—liver cancer	0.0088	0.147	CbGbCtD
Cevimeline—Abdominal pain—Sorafenib—liver cancer	0.00102	0.00136	CcSEcCtD
Cevimeline—Body temperature increased—Sorafenib—liver cancer	0.00102	0.00136	CcSEcCtD
Cevimeline—Renal impairment—Epirubicin—liver cancer	0.00101	0.00136	CcSEcCtD
Cevimeline—Dermatitis bullous—Epirubicin—liver cancer	0.00101	0.00135	CcSEcCtD
Cevimeline—Purpura—Epirubicin—liver cancer	0.001	0.00134	CcSEcCtD
Cevimeline—Vascular purpura—Doxorubicin—liver cancer	0.000999	0.00134	CcSEcCtD
Cevimeline—Eczema—Doxorubicin—liver cancer	0.000994	0.00133	CcSEcCtD
Cevimeline—Eye pain—Doxorubicin—liver cancer	0.00099	0.00133	CcSEcCtD
Cevimeline—Hypoglycaemia—Epirubicin—liver cancer	0.00099	0.00133	CcSEcCtD
Cevimeline—Hyponatraemia—Epirubicin—liver cancer	0.00097	0.0013	CcSEcCtD
Cevimeline—Diplopia—Epirubicin—liver cancer	0.000966	0.00129	CcSEcCtD
Cevimeline—Pain in extremity—Epirubicin—liver cancer	0.000966	0.00129	CcSEcCtD
Cevimeline—Osteoarthritis—Epirubicin—liver cancer	0.000966	0.00129	CcSEcCtD
Cevimeline—Gastrointestinal haemorrhage—Epirubicin—liver cancer	0.000966	0.00129	CcSEcCtD
Cevimeline—Hot flush—Doxorubicin—liver cancer	0.000955	0.00128	CcSEcCtD
Cevimeline—Increased appetite—Doxorubicin—liver cancer	0.000951	0.00127	CcSEcCtD
Cevimeline—Migraine—Epirubicin—liver cancer	0.000951	0.00127	CcSEcCtD
Cevimeline—Affect lability—Epirubicin—liver cancer	0.000951	0.00127	CcSEcCtD
Cevimeline—Menopausal symptoms—Doxorubicin—liver cancer	0.000947	0.00127	CcSEcCtD
Cevimeline—Hypersensitivity—Sorafenib—liver cancer	0.000946	0.00127	CcSEcCtD
Cevimeline—Renal impairment—Doxorubicin—liver cancer	0.000939	0.00126	CcSEcCtD
Cevimeline—Dermatitis bullous—Doxorubicin—liver cancer	0.000935	0.00125	CcSEcCtD
Cevimeline—Face oedema—Epirubicin—liver cancer	0.000932	0.00125	CcSEcCtD
Cevimeline—Purpura—Doxorubicin—liver cancer	0.000927	0.00124	CcSEcCtD
Cevimeline—Asthenia—Sorafenib—liver cancer	0.000922	0.00124	CcSEcCtD
Cevimeline—Hypoglycaemia—Doxorubicin—liver cancer	0.000916	0.00123	CcSEcCtD
Cevimeline—Mood swings—Epirubicin—liver cancer	0.000915	0.00123	CcSEcCtD
Cevimeline—Pruritus—Sorafenib—liver cancer	0.000909	0.00122	CcSEcCtD
Cevimeline—Dehydration—Epirubicin—liver cancer	0.000898	0.0012	CcSEcCtD
Cevimeline—Hyponatraemia—Doxorubicin—liver cancer	0.000897	0.0012	CcSEcCtD
Cevimeline—Osteoarthritis—Doxorubicin—liver cancer	0.000894	0.0012	CcSEcCtD
Cevimeline—Diplopia—Doxorubicin—liver cancer	0.000894	0.0012	CcSEcCtD
Cevimeline—Pain in extremity—Doxorubicin—liver cancer	0.000894	0.0012	CcSEcCtD
Cevimeline—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.000894	0.0012	CcSEcCtD
Cevimeline—Dry skin—Epirubicin—liver cancer	0.000885	0.00119	CcSEcCtD
Cevimeline—Orthostatic hypotension—Epirubicin—liver cancer	0.000882	0.00118	CcSEcCtD
Cevimeline—Migraine—Doxorubicin—liver cancer	0.00088	0.00118	CcSEcCtD
Cevimeline—Affect lability—Doxorubicin—liver cancer	0.00088	0.00118	CcSEcCtD
Cevimeline—Hypokalaemia—Epirubicin—liver cancer	0.000879	0.00118	CcSEcCtD
Cevimeline—Diarrhoea—Sorafenib—liver cancer	0.000879	0.00118	CcSEcCtD
Cevimeline—Face oedema—Doxorubicin—liver cancer	0.000863	0.00116	CcSEcCtD
Cevimeline—Gastritis—Epirubicin—liver cancer	0.000855	0.00115	CcSEcCtD
Cevimeline—Alanine aminotransferase increased—Epirubicin—liver cancer	0.000852	0.00114	CcSEcCtD
Cevimeline—Muscular weakness—Epirubicin—liver cancer	0.000852	0.00114	CcSEcCtD
Cevimeline—Dizziness—Sorafenib—liver cancer	0.000849	0.00114	CcSEcCtD
Cevimeline—Mood swings—Doxorubicin—liver cancer	0.000847	0.00113	CcSEcCtD
Cevimeline—Abdominal distension—Epirubicin—liver cancer	0.00084	0.00113	CcSEcCtD
Cevimeline—Asthma—Epirubicin—liver cancer	0.000835	0.00112	CcSEcCtD
Cevimeline—Dysphagia—Epirubicin—liver cancer	0.000835	0.00112	CcSEcCtD
Cevimeline—Dehydration—Doxorubicin—liver cancer	0.000831	0.00111	CcSEcCtD
Cevimeline—Eosinophilia—Epirubicin—liver cancer	0.000827	0.00111	CcSEcCtD
Cevimeline—Dry skin—Doxorubicin—liver cancer	0.000819	0.0011	CcSEcCtD
Cevimeline—Vomiting—Sorafenib—liver cancer	0.000817	0.00109	CcSEcCtD
Cevimeline—Orthostatic hypotension—Doxorubicin—liver cancer	0.000816	0.00109	CcSEcCtD
Cevimeline—Hypokalaemia—Doxorubicin—liver cancer	0.000813	0.00109	CcSEcCtD
Cevimeline—Angina pectoris—Epirubicin—liver cancer	0.000813	0.00109	CcSEcCtD
Cevimeline—Rash—Sorafenib—liver cancer	0.00081	0.00109	CcSEcCtD
Cevimeline—Dermatitis—Sorafenib—liver cancer	0.000809	0.00108	CcSEcCtD
Cevimeline—Headache—Sorafenib—liver cancer	0.000805	0.00108	CcSEcCtD
Cevimeline—Bronchitis—Epirubicin—liver cancer	0.000803	0.00108	CcSEcCtD
Cevimeline—Gastritis—Doxorubicin—liver cancer	0.000791	0.00106	CcSEcCtD
Cevimeline—Muscular weakness—Doxorubicin—liver cancer	0.000788	0.00106	CcSEcCtD
Cevimeline—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000788	0.00106	CcSEcCtD
Cevimeline—Dysuria—Epirubicin—liver cancer	0.000781	0.00105	CcSEcCtD
Cevimeline—Abdominal distension—Doxorubicin—liver cancer	0.000778	0.00104	CcSEcCtD
Cevimeline—Upper respiratory tract infection—Epirubicin—liver cancer	0.000776	0.00104	CcSEcCtD
Cevimeline—Asthma—Doxorubicin—liver cancer	0.000772	0.00104	CcSEcCtD
Cevimeline—Dysphagia—Doxorubicin—liver cancer	0.000772	0.00104	CcSEcCtD
Cevimeline—Pollakiuria—Epirubicin—liver cancer	0.000771	0.00103	CcSEcCtD
Cevimeline—Eosinophilia—Doxorubicin—liver cancer	0.000765	0.00102	CcSEcCtD
Cevimeline—Nausea—Sorafenib—liver cancer	0.000763	0.00102	CcSEcCtD
Cevimeline—Photosensitivity reaction—Epirubicin—liver cancer	0.000762	0.00102	CcSEcCtD
Cevimeline—Weight increased—Epirubicin—liver cancer	0.00076	0.00102	CcSEcCtD
Cevimeline—Weight decreased—Epirubicin—liver cancer	0.000755	0.00101	CcSEcCtD
Cevimeline—Hyperglycaemia—Epirubicin—liver cancer	0.000753	0.00101	CcSEcCtD
Cevimeline—Angina pectoris—Doxorubicin—liver cancer	0.000752	0.00101	CcSEcCtD
Cevimeline—Pneumonia—Epirubicin—liver cancer	0.000749	0.001	CcSEcCtD
Cevimeline—Bronchitis—Doxorubicin—liver cancer	0.000743	0.000995	CcSEcCtD
Cevimeline—Neuropathy peripheral—Epirubicin—liver cancer	0.00073	0.000978	CcSEcCtD
Cevimeline—Stomatitis—Epirubicin—liver cancer	0.000726	0.000972	CcSEcCtD
Cevimeline—Urinary tract infection—Epirubicin—liver cancer	0.000724	0.00097	CcSEcCtD
Cevimeline—Conjunctivitis—Epirubicin—liver cancer	0.000724	0.00097	CcSEcCtD
Cevimeline—Dysuria—Doxorubicin—liver cancer	0.000722	0.000968	CcSEcCtD
Cevimeline—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000718	0.000962	CcSEcCtD
Cevimeline—Pollakiuria—Doxorubicin—liver cancer	0.000714	0.000956	CcSEcCtD
Cevimeline—Haematuria—Epirubicin—liver cancer	0.00071	0.000951	CcSEcCtD
Cevimeline—Photosensitivity reaction—Doxorubicin—liver cancer	0.000705	0.000945	CcSEcCtD
Cevimeline—Weight increased—Doxorubicin—liver cancer	0.000703	0.000942	CcSEcCtD
Cevimeline—Epistaxis—Epirubicin—liver cancer	0.000702	0.000941	CcSEcCtD
Cevimeline—Weight decreased—Doxorubicin—liver cancer	0.000699	0.000936	CcSEcCtD
Cevimeline—Sinusitis—Epirubicin—liver cancer	0.000698	0.000936	CcSEcCtD
Cevimeline—Hyperglycaemia—Doxorubicin—liver cancer	0.000697	0.000934	CcSEcCtD
Cevimeline—Agranulocytosis—Epirubicin—liver cancer	0.000695	0.000931	CcSEcCtD
Cevimeline—Pneumonia—Doxorubicin—liver cancer	0.000693	0.000928	CcSEcCtD
Cevimeline—Neuropathy peripheral—Doxorubicin—liver cancer	0.000675	0.000905	CcSEcCtD
Cevimeline—Haemoglobin—Epirubicin—liver cancer	0.000672	0.0009	CcSEcCtD
Cevimeline—Stomatitis—Doxorubicin—liver cancer	0.000671	0.0009	CcSEcCtD
Cevimeline—Rhinitis—Epirubicin—liver cancer	0.00067	0.000898	CcSEcCtD
Cevimeline—Urinary tract infection—Doxorubicin—liver cancer	0.000669	0.000897	CcSEcCtD
Cevimeline—Conjunctivitis—Doxorubicin—liver cancer	0.000669	0.000897	CcSEcCtD
Cevimeline—Haemorrhage—Epirubicin—liver cancer	0.000668	0.000895	CcSEcCtD
Cevimeline—Hypoaesthesia—Epirubicin—liver cancer	0.000665	0.000891	CcSEcCtD
Cevimeline—Pharyngitis—Epirubicin—liver cancer	0.000663	0.000889	CcSEcCtD
Cevimeline—Oedema peripheral—Epirubicin—liver cancer	0.000658	0.000882	CcSEcCtD
Cevimeline—Haematuria—Doxorubicin—liver cancer	0.000657	0.00088	CcSEcCtD
Cevimeline—Urethral disorder—Epirubicin—liver cancer	0.000655	0.000878	CcSEcCtD
Cevimeline—Epistaxis—Doxorubicin—liver cancer	0.00065	0.00087	CcSEcCtD
Cevimeline—Sinusitis—Doxorubicin—liver cancer	0.000646	0.000866	CcSEcCtD
Cevimeline—Visual impairment—Epirubicin—liver cancer	0.000644	0.000863	CcSEcCtD
Cevimeline—Agranulocytosis—Doxorubicin—liver cancer	0.000643	0.000861	CcSEcCtD
Cevimeline—Eye disorder—Epirubicin—liver cancer	0.000624	0.000837	CcSEcCtD
Cevimeline—Tinnitus—Epirubicin—liver cancer	0.000623	0.000835	CcSEcCtD
Cevimeline—Haemoglobin—Doxorubicin—liver cancer	0.000621	0.000833	CcSEcCtD
Cevimeline—Flushing—Epirubicin—liver cancer	0.00062	0.000831	CcSEcCtD
Cevimeline—Cardiac disorder—Epirubicin—liver cancer	0.00062	0.000831	CcSEcCtD
Cevimeline—Rhinitis—Doxorubicin—liver cancer	0.00062	0.000831	CcSEcCtD
Cevimeline—Haemorrhage—Doxorubicin—liver cancer	0.000618	0.000828	CcSEcCtD
Cevimeline—Hypoaesthesia—Doxorubicin—liver cancer	0.000615	0.000824	CcSEcCtD
Cevimeline—Pharyngitis—Doxorubicin—liver cancer	0.000614	0.000822	CcSEcCtD
Cevimeline—Oedema peripheral—Doxorubicin—liver cancer	0.000609	0.000816	CcSEcCtD
Cevimeline—Angiopathy—Epirubicin—liver cancer	0.000606	0.000812	CcSEcCtD
Cevimeline—Urethral disorder—Doxorubicin—liver cancer	0.000606	0.000812	CcSEcCtD
Cevimeline—Chills—Epirubicin—liver cancer	0.0006	0.000803	CcSEcCtD
Cevimeline—Arrhythmia—Epirubicin—liver cancer	0.000597	0.0008	CcSEcCtD
Cevimeline—Visual impairment—Doxorubicin—liver cancer	0.000596	0.000798	CcSEcCtD
Cevimeline—Alopecia—Epirubicin—liver cancer	0.00059	0.000791	CcSEcCtD
Cevimeline—Malnutrition—Epirubicin—liver cancer	0.000582	0.000779	CcSEcCtD
Cevimeline—Eye disorder—Doxorubicin—liver cancer	0.000578	0.000774	CcSEcCtD
Cevimeline—Tinnitus—Doxorubicin—liver cancer	0.000576	0.000772	CcSEcCtD
Cevimeline—Flushing—Doxorubicin—liver cancer	0.000574	0.000769	CcSEcCtD
Cevimeline—Cardiac disorder—Doxorubicin—liver cancer	0.000574	0.000769	CcSEcCtD
Cevimeline—Flatulence—Epirubicin—liver cancer	0.000573	0.000768	CcSEcCtD
Cevimeline—Dysgeusia—Epirubicin—liver cancer	0.00057	0.000763	CcSEcCtD
Cevimeline—Back pain—Epirubicin—liver cancer	0.000563	0.000754	CcSEcCtD
Cevimeline—Angiopathy—Doxorubicin—liver cancer	0.000561	0.000752	CcSEcCtD
Cevimeline—Muscle spasms—Epirubicin—liver cancer	0.000559	0.000749	CcSEcCtD
Cevimeline—Chills—Doxorubicin—liver cancer	0.000555	0.000743	CcSEcCtD
Cevimeline—Arrhythmia—Doxorubicin—liver cancer	0.000552	0.00074	CcSEcCtD
Cevimeline—Alopecia—Doxorubicin—liver cancer	0.000546	0.000732	CcSEcCtD
Cevimeline—Ill-defined disorder—Epirubicin—liver cancer	0.00054	0.000723	CcSEcCtD
Cevimeline—Malnutrition—Doxorubicin—liver cancer	0.000538	0.000721	CcSEcCtD
Cevimeline—Anaemia—Epirubicin—liver cancer	0.000538	0.00072	CcSEcCtD
Cevimeline—Agitation—Epirubicin—liver cancer	0.000535	0.000716	CcSEcCtD
Cevimeline—Flatulence—Doxorubicin—liver cancer	0.00053	0.000711	CcSEcCtD
Cevimeline—Dysgeusia—Doxorubicin—liver cancer	0.000527	0.000706	CcSEcCtD
Cevimeline—Malaise—Epirubicin—liver cancer	0.000525	0.000703	CcSEcCtD
Cevimeline—Vertigo—Epirubicin—liver cancer	0.000523	0.0007	CcSEcCtD
Cevimeline—Syncope—Epirubicin—liver cancer	0.000522	0.000699	CcSEcCtD
Cevimeline—Leukopenia—Epirubicin—liver cancer	0.000521	0.000698	CcSEcCtD
Cevimeline—Back pain—Doxorubicin—liver cancer	0.000521	0.000698	CcSEcCtD
Cevimeline—Muscle spasms—Doxorubicin—liver cancer	0.000517	0.000693	CcSEcCtD
Cevimeline—Palpitations—Epirubicin—liver cancer	0.000514	0.000689	CcSEcCtD
Cevimeline—Loss of consciousness—Epirubicin—liver cancer	0.000511	0.000685	CcSEcCtD
Cevimeline—Cough—Epirubicin—liver cancer	0.000508	0.00068	CcSEcCtD
Cevimeline—Convulsion—Epirubicin—liver cancer	0.000504	0.000675	CcSEcCtD
Cevimeline—Hypertension—Epirubicin—liver cancer	0.000502	0.000673	CcSEcCtD
Cevimeline—Ill-defined disorder—Doxorubicin—liver cancer	0.000499	0.000669	CcSEcCtD
Cevimeline—Anaemia—Doxorubicin—liver cancer	0.000497	0.000667	CcSEcCtD
Cevimeline—Chest pain—Epirubicin—liver cancer	0.000495	0.000664	CcSEcCtD
Cevimeline—Arthralgia—Epirubicin—liver cancer	0.000495	0.000664	CcSEcCtD
Cevimeline—Myalgia—Epirubicin—liver cancer	0.000495	0.000664	CcSEcCtD
Cevimeline—Agitation—Doxorubicin—liver cancer	0.000495	0.000663	CcSEcCtD
Cevimeline—Anxiety—Epirubicin—liver cancer	0.000494	0.000661	CcSEcCtD
Cevimeline—Discomfort—Epirubicin—liver cancer	0.000489	0.000656	CcSEcCtD
Cevimeline—Malaise—Doxorubicin—liver cancer	0.000485	0.00065	CcSEcCtD
Cevimeline—Vertigo—Doxorubicin—liver cancer	0.000484	0.000648	CcSEcCtD
Cevimeline—Syncope—Doxorubicin—liver cancer	0.000483	0.000647	CcSEcCtD
Cevimeline—Leukopenia—Doxorubicin—liver cancer	0.000482	0.000646	CcSEcCtD
Cevimeline—Confusional state—Epirubicin—liver cancer	0.000479	0.000641	CcSEcCtD
Cevimeline—Palpitations—Doxorubicin—liver cancer	0.000476	0.000637	CcSEcCtD
Cevimeline—Oedema—Epirubicin—liver cancer	0.000475	0.000636	CcSEcCtD
Cevimeline—Loss of consciousness—Doxorubicin—liver cancer	0.000473	0.000634	CcSEcCtD
Cevimeline—Infection—Epirubicin—liver cancer	0.000472	0.000632	CcSEcCtD
Cevimeline—Cough—Doxorubicin—liver cancer	0.00047	0.000629	CcSEcCtD
Cevimeline—Shock—Epirubicin—liver cancer	0.000467	0.000626	CcSEcCtD
Cevimeline—Convulsion—Doxorubicin—liver cancer	0.000466	0.000625	CcSEcCtD
Cevimeline—Nervous system disorder—Epirubicin—liver cancer	0.000466	0.000624	CcSEcCtD
Cevimeline—Thrombocytopenia—Epirubicin—liver cancer	0.000465	0.000623	CcSEcCtD
Cevimeline—Hypertension—Doxorubicin—liver cancer	0.000465	0.000623	CcSEcCtD
Cevimeline—Tachycardia—Epirubicin—liver cancer	0.000463	0.000621	CcSEcCtD
Cevimeline—Skin disorder—Epirubicin—liver cancer	0.000461	0.000618	CcSEcCtD
Cevimeline—Hyperhidrosis—Epirubicin—liver cancer	0.000459	0.000615	CcSEcCtD
Cevimeline—Chest pain—Doxorubicin—liver cancer	0.000458	0.000614	CcSEcCtD
Cevimeline—Myalgia—Doxorubicin—liver cancer	0.000458	0.000614	CcSEcCtD
Cevimeline—Arthralgia—Doxorubicin—liver cancer	0.000458	0.000614	CcSEcCtD
Cevimeline—Anxiety—Doxorubicin—liver cancer	0.000457	0.000612	CcSEcCtD
Cevimeline—Discomfort—Doxorubicin—liver cancer	0.000453	0.000607	CcSEcCtD
Cevimeline—Anorexia—Epirubicin—liver cancer	0.000453	0.000606	CcSEcCtD
Cevimeline—Hypotension—Epirubicin—liver cancer	0.000444	0.000594	CcSEcCtD
Cevimeline—Confusional state—Doxorubicin—liver cancer	0.000443	0.000593	CcSEcCtD
Cevimeline—Oedema—Doxorubicin—liver cancer	0.000439	0.000589	CcSEcCtD
Cevimeline—Infection—Doxorubicin—liver cancer	0.000436	0.000585	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000433	0.00058	CcSEcCtD
Cevimeline—Shock—Doxorubicin—liver cancer	0.000432	0.000579	CcSEcCtD
Cevimeline—Nervous system disorder—Doxorubicin—liver cancer	0.000431	0.000577	CcSEcCtD
Cevimeline—Thrombocytopenia—Doxorubicin—liver cancer	0.00043	0.000576	CcSEcCtD
Cevimeline—Insomnia—Epirubicin—liver cancer	0.000429	0.000575	CcSEcCtD
Cevimeline—Tachycardia—Doxorubicin—liver cancer	0.000429	0.000574	CcSEcCtD
Cevimeline—Skin disorder—Doxorubicin—liver cancer	0.000427	0.000572	CcSEcCtD
Cevimeline—Paraesthesia—Epirubicin—liver cancer	0.000426	0.000571	CcSEcCtD
Cevimeline—Hyperhidrosis—Doxorubicin—liver cancer	0.000425	0.000569	CcSEcCtD
Cevimeline—Dyspnoea—Epirubicin—liver cancer	0.000423	0.000567	CcSEcCtD
Cevimeline—Somnolence—Epirubicin—liver cancer	0.000422	0.000566	CcSEcCtD
Cevimeline—Anorexia—Doxorubicin—liver cancer	0.000419	0.000561	CcSEcCtD
Cevimeline—Dyspepsia—Epirubicin—liver cancer	0.000418	0.00056	CcSEcCtD
Cevimeline—Decreased appetite—Epirubicin—liver cancer	0.000413	0.000553	CcSEcCtD
Cevimeline—Hypotension—Doxorubicin—liver cancer	0.00041	0.00055	CcSEcCtD
Cevimeline—Fatigue—Epirubicin—liver cancer	0.000409	0.000548	CcSEcCtD
Cevimeline—Constipation—Epirubicin—liver cancer	0.000406	0.000544	CcSEcCtD
Cevimeline—Pain—Epirubicin—liver cancer	0.000406	0.000544	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.0004	0.000536	CcSEcCtD
Cevimeline—Insomnia—Doxorubicin—liver cancer	0.000397	0.000532	CcSEcCtD
Cevimeline—Paraesthesia—Doxorubicin—liver cancer	0.000394	0.000529	CcSEcCtD
Cevimeline—Dyspnoea—Doxorubicin—liver cancer	0.000392	0.000525	CcSEcCtD
Cevimeline—Feeling abnormal—Epirubicin—liver cancer	0.000391	0.000524	CcSEcCtD
Cevimeline—Somnolence—Doxorubicin—liver cancer	0.000391	0.000523	CcSEcCtD
Cevimeline—Gastrointestinal pain—Epirubicin—liver cancer	0.000388	0.00052	CcSEcCtD
Cevimeline—Dyspepsia—Doxorubicin—liver cancer	0.000387	0.000518	CcSEcCtD
Cevimeline—Decreased appetite—Doxorubicin—liver cancer	0.000382	0.000512	CcSEcCtD
Cevimeline—Fatigue—Doxorubicin—liver cancer	0.000379	0.000507	CcSEcCtD
Cevimeline—Urticaria—Epirubicin—liver cancer	0.000377	0.000505	CcSEcCtD
Cevimeline—Pain—Doxorubicin—liver cancer	0.000376	0.000503	CcSEcCtD
Cevimeline—Constipation—Doxorubicin—liver cancer	0.000376	0.000503	CcSEcCtD
Cevimeline—Abdominal pain—Epirubicin—liver cancer	0.000375	0.000503	CcSEcCtD
Cevimeline—Body temperature increased—Epirubicin—liver cancer	0.000375	0.000503	CcSEcCtD
Cevimeline—Feeling abnormal—Doxorubicin—liver cancer	0.000362	0.000485	CcSEcCtD
Cevimeline—Gastrointestinal pain—Doxorubicin—liver cancer	0.000359	0.000481	CcSEcCtD
Cevimeline—Hypersensitivity—Epirubicin—liver cancer	0.00035	0.000469	CcSEcCtD
Cevimeline—Urticaria—Doxorubicin—liver cancer	0.000349	0.000468	CcSEcCtD
Cevimeline—Abdominal pain—Doxorubicin—liver cancer	0.000347	0.000465	CcSEcCtD
Cevimeline—Body temperature increased—Doxorubicin—liver cancer	0.000347	0.000465	CcSEcCtD
Cevimeline—Asthenia—Epirubicin—liver cancer	0.000341	0.000456	CcSEcCtD
Cevimeline—Pruritus—Epirubicin—liver cancer	0.000336	0.00045	CcSEcCtD
Cevimeline—Diarrhoea—Epirubicin—liver cancer	0.000325	0.000435	CcSEcCtD
Cevimeline—Hypersensitivity—Doxorubicin—liver cancer	0.000324	0.000434	CcSEcCtD
Cevimeline—Asthenia—Doxorubicin—liver cancer	0.000315	0.000422	CcSEcCtD
Cevimeline—Dizziness—Epirubicin—liver cancer	0.000314	0.000421	CcSEcCtD
Cevimeline—Pruritus—Doxorubicin—liver cancer	0.000311	0.000416	CcSEcCtD
Cevimeline—Vomiting—Epirubicin—liver cancer	0.000302	0.000404	CcSEcCtD
Cevimeline—Diarrhoea—Doxorubicin—liver cancer	0.000301	0.000403	CcSEcCtD
Cevimeline—Rash—Epirubicin—liver cancer	0.000299	0.000401	CcSEcCtD
Cevimeline—Dermatitis—Epirubicin—liver cancer	0.000299	0.000401	CcSEcCtD
Cevimeline—Headache—Epirubicin—liver cancer	0.000297	0.000399	CcSEcCtD
Cevimeline—Dizziness—Doxorubicin—liver cancer	0.00029	0.000389	CcSEcCtD
Cevimeline—Nausea—Epirubicin—liver cancer	0.000282	0.000378	CcSEcCtD
Cevimeline—Vomiting—Doxorubicin—liver cancer	0.000279	0.000374	CcSEcCtD
Cevimeline—Rash—Doxorubicin—liver cancer	0.000277	0.000371	CcSEcCtD
Cevimeline—Dermatitis—Doxorubicin—liver cancer	0.000277	0.000371	CcSEcCtD
Cevimeline—Headache—Doxorubicin—liver cancer	0.000275	0.000369	CcSEcCtD
Cevimeline—Nausea—Doxorubicin—liver cancer	0.000261	0.00035	CcSEcCtD
Cevimeline—CYP3A4—Metapathway biotransformation—GSTP1—liver cancer	0.000142	0.000735	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—NR1H4—liver cancer	0.000141	0.000726	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GSTA3—liver cancer	0.000138	0.000713	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—EPT1—liver cancer	0.000135	0.000698	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—SHC3—liver cancer	0.000133	0.000687	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—PIK3CB—liver cancer	0.000133	0.000685	CbGpPWpGaD
Cevimeline—CYP3A4—Biological oxidations—GSTM1—liver cancer	0.000133	0.000685	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—SHC3—liver cancer	0.000133	0.000685	CbGpPWpGaD
Cevimeline—CHRM1—Regulation of Actin Cytoskeleton—PIK3CA—liver cancer	0.000132	0.000684	CbGpPWpGaD
Cevimeline—CHRM3—Regulation of Actin Cytoskeleton—PIK3CA—liver cancer	0.000132	0.000682	CbGpPWpGaD
Cevimeline—CYP3A4—Metapathway biotransformation—GSTM1—liver cancer	0.000131	0.000675	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—TAT—liver cancer	0.000128	0.000662	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GSTA4—liver cancer	0.000126	0.000653	CbGpPWpGaD
Cevimeline—CYP3A4—Biological oxidations—CYP1A1—liver cancer	0.000126	0.000649	CbGpPWpGaD
Cevimeline—CHRM1—GPCR ligand binding—F2—liver cancer	0.000125	0.000643	CbGpPWpGaD
Cevimeline—CHRM3—GPCR ligand binding—F2—liver cancer	0.000124	0.000641	CbGpPWpGaD
Cevimeline—CYP3A4—Metapathway biotransformation—CYP1A1—liver cancer	0.000124	0.00064	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GSTA2—liver cancer	0.000123	0.000636	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GSTA1—liver cancer	0.000119	0.000614	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—NAT2—liver cancer	0.000118	0.000607	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—ALDOB—liver cancer	0.000113	0.000582	CbGpPWpGaD
Cevimeline—CHRM1—G alpha (q) signalling events—PIK3CA—liver cancer	0.00011	0.00057	CbGpPWpGaD
Cevimeline—CHRM3—G alpha (q) signalling events—PIK3CA—liver cancer	0.00011	0.000568	CbGpPWpGaD
Cevimeline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—liver cancer	0.000108	0.000555	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CRABP1—liver cancer	0.000108	0.000555	CbGpPWpGaD
Cevimeline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—liver cancer	0.000107	0.000553	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—FST—liver cancer	0.000103	0.000533	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—FST—liver cancer	0.000103	0.000532	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—PRKCE—liver cancer	0.000101	0.000524	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—PRKCE—liver cancer	0.000101	0.000522	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—TP53—liver cancer	0.000101	0.000521	CbGpPWpGaD
Cevimeline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—liver cancer	9.88e-05	0.00051	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TRIO—liver cancer	9.86e-05	0.000509	CbGpPWpGaD
Cevimeline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—liver cancer	9.85e-05	0.000508	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TRIO—liver cancer	9.83e-05	0.000507	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CCR4—liver cancer	9.45e-05	0.000488	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CCR4—liver cancer	9.42e-05	0.000486	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—UGDH—liver cancer	9.41e-05	0.000486	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—HPGDS—liver cancer	9.4e-05	0.000485	CbGpPWpGaD
Cevimeline—CHRM1—Circadian rythm related genes—IL6—liver cancer	9.23e-05	0.000477	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—PRKCE—liver cancer	9.21e-05	0.000476	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—PRKCE—liver cancer	9.18e-05	0.000474	CbGpPWpGaD
Cevimeline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—liver cancer	9.14e-05	0.000472	CbGpPWpGaD
Cevimeline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—liver cancer	9.11e-05	0.00047	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—CSF2—liver cancer	8.98e-05	0.000463	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—CSF2—liver cancer	8.95e-05	0.000462	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—EPT1—liver cancer	8.85e-05	0.000457	CbGpPWpGaD
Cevimeline—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—liver cancer	8.75e-05	0.000452	CbGpPWpGaD
Cevimeline—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—liver cancer	8.72e-05	0.00045	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GLUL—liver cancer	8.72e-05	0.00045	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CPT1B—liver cancer	8.72e-05	0.00045	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—NR1H4—liver cancer	8.41e-05	0.000434	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—TAT—liver cancer	8.39e-05	0.000433	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PSMD10—liver cancer	8.38e-05	0.000432	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PSMA4—liver cancer	8.38e-05	0.000432	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GSTA3—liver cancer	8.27e-05	0.000427	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—CSF2—liver cancer	8.15e-05	0.000421	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GOT2—liver cancer	8.15e-05	0.00042	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—CSF2—liver cancer	8.13e-05	0.000419	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—PIK3CA—liver cancer	8.09e-05	0.000418	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CYP2E1—liver cancer	7.66e-05	0.000395	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GSTA4—liver cancer	7.56e-05	0.00039	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—ADAM17—liver cancer	7.47e-05	0.000386	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—ADAM17—liver cancer	7.45e-05	0.000384	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GSTA2—liver cancer	7.37e-05	0.00038	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CYCS—liver cancer	7.17e-05	0.00037	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GSTA1—liver cancer	7.11e-05	0.000367	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—F2—liver cancer	7.04e-05	0.000364	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GOT1—liver cancer	7.03e-05	0.000363	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GGT1—liver cancer	7.03e-05	0.000363	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—NAT2—liver cancer	7.03e-05	0.000363	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PSMA4—liver cancer	7.03e-05	0.000363	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PSMD10—liver cancer	7.03e-05	0.000363	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—F2—liver cancer	7.02e-05	0.000362	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PSMD10—liver cancer	7e-05	0.000361	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PSMA4—liver cancer	7e-05	0.000361	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—PIK3CG—liver cancer	6.74e-05	0.000348	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ALDOB—liver cancer	6.74e-05	0.000348	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—PIK3CG—liver cancer	6.72e-05	0.000347	CbGpPWpGaD
Cevimeline—FMO1—Metabolism—AKT1—liver cancer	6.61e-05	0.000341	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CRABP1—liver cancer	6.43e-05	0.000332	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—F2—liver cancer	6.4e-05	0.00033	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—F2—liver cancer	6.38e-05	0.000329	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GSTP1—liver cancer	6.32e-05	0.000326	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—HMOX1—liver cancer	6.23e-05	0.000322	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—PIK3CG—liver cancer	6.12e-05	0.000316	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—PIK3CG—liver cancer	6.1e-05	0.000315	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—PIK3CD—liver cancer	5.93e-05	0.000306	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—PIK3CD—liver cancer	5.91e-05	0.000305	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GSTM1—liver cancer	5.81e-05	0.0003	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CPT1B—liver cancer	5.7e-05	0.000294	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GLUL—liver cancer	5.7e-05	0.000294	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—HPGDS—liver cancer	5.62e-05	0.00029	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CYP1A1—liver cancer	5.5e-05	0.000284	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—NR1H4—liver cancer	5.5e-05	0.000284	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PRKCE—liver cancer	5.44e-05	0.000281	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PRKCE—liver cancer	5.43e-05	0.00028	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GSTA3—liver cancer	5.4e-05	0.000279	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—PIK3CD—liver cancer	5.38e-05	0.000278	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—PIK3CD—liver cancer	5.36e-05	0.000277	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—PIK3CB—liver cancer	5.17e-05	0.000267	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IGF2—liver cancer	5.16e-05	0.000266	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—PIK3CB—liver cancer	5.15e-05	0.000266	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IGF2—liver cancer	5.14e-05	0.000265	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—MTHFR—liver cancer	5.13e-05	0.000265	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PPARA—liver cancer	5.03e-05	0.00026	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PSMD10—liver cancer	5.01e-05	0.000258	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PSMA4—liver cancer	5.01e-05	0.000258	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GSTA4—liver cancer	4.94e-05	0.000255	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GOT2—liver cancer	4.87e-05	0.000251	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GSTA2—liver cancer	4.82e-05	0.000249	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CSF2—liver cancer	4.82e-05	0.000249	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—RAF1—liver cancer	4.8e-05	0.000248	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CSF2—liver cancer	4.8e-05	0.000248	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—RAF1—liver cancer	4.79e-05	0.000247	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—H2AFX—liver cancer	4.75e-05	0.000245	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—IL2—liver cancer	4.74e-05	0.000245	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—H2AFX—liver cancer	4.73e-05	0.000244	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—IL2—liver cancer	4.73e-05	0.000244	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—PIK3CB—liver cancer	4.69e-05	0.000242	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—PIK3CB—liver cancer	4.68e-05	0.000241	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GSTA1—liver cancer	4.65e-05	0.00024	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—NAT2—liver cancer	4.6e-05	0.000237	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CYP2E1—liver cancer	4.58e-05	0.000236	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ALDOB—liver cancer	4.41e-05	0.000227	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PIK3CG—liver cancer	4.31e-05	0.000222	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—IL2—liver cancer	4.31e-05	0.000222	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—IL2—liver cancer	4.29e-05	0.000222	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TERT—liver cancer	4.29e-05	0.000221	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CYCS—liver cancer	4.29e-05	0.000221	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TERT—liver cancer	4.28e-05	0.000221	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GGT1—liver cancer	4.21e-05	0.000217	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GOT1—liver cancer	4.21e-05	0.000217	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CRABP1—liver cancer	4.2e-05	0.000217	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PPARG—liver cancer	4.16e-05	0.000215	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—KDR—liver cancer	3.93e-05	0.000203	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—KDR—liver cancer	3.91e-05	0.000202	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MAPK14—liver cancer	3.9e-05	0.000201	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MAPK14—liver cancer	3.89e-05	0.000201	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—ESR1—liver cancer	3.83e-05	0.000197	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—ESR1—liver cancer	3.81e-05	0.000197	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PIK3CD—liver cancer	3.79e-05	0.000196	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—F2—liver cancer	3.78e-05	0.000195	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GSTP1—liver cancer	3.78e-05	0.000195	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—F2—liver cancer	3.77e-05	0.000194	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—ALB—liver cancer	3.74e-05	0.000193	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—HMOX1—liver cancer	3.73e-05	0.000192	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—HPGDS—liver cancer	3.67e-05	0.00019	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—APC—liver cancer	3.62e-05	0.000187	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PIK3CG—liver cancer	3.62e-05	0.000187	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—APC—liver cancer	3.6e-05	0.000186	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PIK3CG—liver cancer	3.6e-05	0.000186	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GSTM1—liver cancer	3.47e-05	0.000179	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—BRAF—liver cancer	3.4e-05	0.000175	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—BRAF—liver cancer	3.39e-05	0.000175	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PIK3CB—liver cancer	3.3e-05	0.00017	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CYP1A1—liver cancer	3.29e-05	0.00017	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PSMD10—liver cancer	3.27e-05	0.000169	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PSMA4—liver cancer	3.27e-05	0.000169	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GOT2—liver cancer	3.19e-05	0.000164	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PIK3CD—liver cancer	3.18e-05	0.000164	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PIK3CD—liver cancer	3.17e-05	0.000164	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—PIK3CA—liver cancer	3.15e-05	0.000162	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—SERPINE1—liver cancer	3.14e-05	0.000162	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—PIK3CA—liver cancer	3.14e-05	0.000162	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—SERPINE1—liver cancer	3.13e-05	0.000162	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—KRAS—liver cancer	3.11e-05	0.000161	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—KRAS—liver cancer	3.1e-05	0.00016	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—MTHFR—liver cancer	3.07e-05	0.000158	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PPARA—liver cancer	3.01e-05	0.000155	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CYP2E1—liver cancer	2.99e-05	0.000155	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—PIK3CA—liver cancer	2.86e-05	0.000148	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—PIK3CA—liver cancer	2.85e-05	0.000147	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—RAF1—liver cancer	2.84e-05	0.000146	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—RAF1—liver cancer	2.83e-05	0.000146	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CYCS—liver cancer	2.8e-05	0.000145	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MTOR—liver cancer	2.77e-05	0.000143	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PIK3CB—liver cancer	2.77e-05	0.000143	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MTOR—liver cancer	2.76e-05	0.000143	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PIK3CB—liver cancer	2.76e-05	0.000143	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GGT1—liver cancer	2.75e-05	0.000142	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GOT1—liver cancer	2.75e-05	0.000142	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—HRAS—liver cancer	2.65e-05	0.000137	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—HRAS—liver cancer	2.64e-05	0.000136	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CDKN1B—liver cancer	2.6e-05	0.000134	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CDKN1B—liver cancer	2.59e-05	0.000134	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PIK3CG—liver cancer	2.58e-05	0.000133	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—AKT1—liver cancer	2.57e-05	0.000133	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—AKT1—liver cancer	2.56e-05	0.000132	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CASP3—liver cancer	2.55e-05	0.000132	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IL2—liver cancer	2.54e-05	0.000131	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CASP3—liver cancer	2.54e-05	0.000131	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IL2—liver cancer	2.54e-05	0.000131	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—IL6—liver cancer	2.53e-05	0.000131	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—IL6—liver cancer	2.52e-05	0.00013	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PPARG—liver cancer	2.49e-05	0.000128	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CCND1—liver cancer	2.48e-05	0.000128	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—JUN—liver cancer	2.48e-05	0.000128	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CCND1—liver cancer	2.47e-05	0.000128	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GSTP1—liver cancer	2.47e-05	0.000127	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—JUN—liver cancer	2.47e-05	0.000127	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CTNNB1—liver cancer	2.46e-05	0.000127	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CTNNB1—liver cancer	2.45e-05	0.000126	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—HMOX1—liver cancer	2.44e-05	0.000126	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MMP9—liver cancer	2.41e-05	0.000124	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MMP9—liver cancer	2.4e-05	0.000124	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CDKN1A—liver cancer	2.4e-05	0.000124	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CDKN1A—liver cancer	2.39e-05	0.000123	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MAPK8—liver cancer	2.34e-05	0.000121	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—AKT1—liver cancer	2.34e-05	0.000121	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MAPK8—liver cancer	2.33e-05	0.00012	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—AKT1—liver cancer	2.33e-05	0.00012	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GSTM1—liver cancer	2.27e-05	0.000117	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PIK3CD—liver cancer	2.27e-05	0.000117	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ALB—liver cancer	2.24e-05	0.000115	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—VEGFA—liver cancer	2.16e-05	0.000112	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—VEGFA—liver cancer	2.16e-05	0.000111	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CYP1A1—liver cancer	2.15e-05	0.000111	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—STAT3—liver cancer	2.14e-05	0.000111	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—STAT3—liver cancer	2.13e-05	0.00011	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PIK3CA—liver cancer	2.01e-05	0.000104	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—MTHFR—liver cancer	2.01e-05	0.000104	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MYC—liver cancer	1.99e-05	0.000103	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TGFB1—liver cancer	1.98e-05	0.000102	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MYC—liver cancer	1.98e-05	0.000102	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TGFB1—liver cancer	1.98e-05	0.000102	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PIK3CB—liver cancer	1.97e-05	0.000102	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PPARA—liver cancer	1.97e-05	0.000102	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—KRAS—liver cancer	1.84e-05	9.49e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—KRAS—liver cancer	1.83e-05	9.46e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PIK3CA—liver cancer	1.69e-05	8.72e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PIK3CG—liver cancer	1.69e-05	8.7e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PIK3CA—liver cancer	1.68e-05	8.69e-05	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—AKT1—liver cancer	1.64e-05	8.49e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TP53—liver cancer	1.63e-05	8.43e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TP53—liver cancer	1.63e-05	8.41e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PPARG—liver cancer	1.63e-05	8.39e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—HRAS—liver cancer	1.56e-05	8.07e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—HRAS—liver cancer	1.56e-05	8.04e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IL6—liver cancer	1.5e-05	7.72e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IL6—liver cancer	1.49e-05	7.69e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PIK3CD—liver cancer	1.48e-05	7.65e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ALB—liver cancer	1.46e-05	7.55e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—AKT1—liver cancer	1.38e-05	7.12e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—AKT1—liver cancer	1.38e-05	7.1e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PIK3CB—liver cancer	1.29e-05	6.66e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PIK3CA—liver cancer	1.2e-05	6.21e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—AKT1—liver cancer	9.84e-06	5.08e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PIK3CA—liver cancer	7.87e-06	4.06e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—AKT1—liver cancer	6.43e-06	3.32e-05	CbGpPWpGaD
